These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26446628)

  • 1. Can Prostate-Specific Antigen Kinetics before Prostate Biopsy Predict the Malignant Potential of Prostate Cancer?
    Kim SJ; Jeong TY; Yoo DS; Park J; Cho S; Kang SH; Lee SH; Jeon SH; Lee TY; Park SY
    Yonsei Med J; 2015 Nov; 56(6):1492-6. PubMed ID: 26446628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10 ng/ml: results of a prospective study in a clinical setting.
    Guazzoni G; Nava L; Lazzeri M; Scattoni V; Lughezzani G; Maccagnano C; Dorigatti F; Ceriotti F; Pontillo M; Bini V; Freschi M; Montorsi F; Rigatti P
    Eur Urol; 2011 Aug; 60(2):214-22. PubMed ID: 21482022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.
    Auprich M; Augustin H; Budäus L; Kluth L; Mannweiler S; Shariat SF; Fisch M; Graefen M; Pummer K; Chun FK
    BJU Int; 2012 Jun; 109(11):1627-35. PubMed ID: 21939492
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of prostate-specific antigen, its density and the Gleason score in the prediction of extracapsular disease in prostate carcinoma.
    Akdaş A; Tarcan T; Türkeri L; Biren T; Küllü S; Ilker Y
    Eur Urol; 1997; 31(3):311-6. PubMed ID: 9129922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is there any association between National Institute of Health category IV prostatitis and prostate-specific antigen levels in patients with low-risk localized prostate cancer?
    Doluoglu OG; Ceylan C; Kilinc F; Gazel E; Resorlu B; Odabas O
    Int Braz J Urol; 2016; 42(2):346-50. PubMed ID: 27256190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of the digital rectal examination as diagnostic test for prostate cancer detection in obese patients.
    Dell'Atti L
    J BUON; 2015; 20(6):1601-5. PubMed ID: 26854458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies.
    Servian P; Celma A; Planas J; Placer J; de Torres IM; Morote J
    Prostate; 2016 Dec; 76(16):1501-1506. PubMed ID: 27404228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simple Risk Stratification to Detect Prostate Cancer with High Gleason Score in Repeat Biopsies in a Population Screening Follow-up Study.
    Kitagawa Y; Urata S; Mizokami A; Nakashima K; Koshida K; Nakashima T; Miyazaki K; Namiki M
    Anticancer Res; 2015 Sep; 35(9):5031-6. PubMed ID: 26254404
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.
    D'Amico AV; Whittington R; Malkowicz SB; Schultz D; Schnall M; Tomaszewski JE; Wein A
    J Urol; 1995 Jul; 154(1):131-8. PubMed ID: 7539857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter.
    Ahyai SA; Graefen M; Steuber T; Haese A; Schlomm T; Walz J; Köllermann J; Briganti A; Zacharias M; Friedrich MG; Karakiewicz PI; Montorsi F; Huland H; Chun FK
    Eur Urol; 2008 Apr; 53(4):750-7. PubMed ID: 17964070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen vs prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy.
    Oh JJ; Hong SK; Lee JK; Lee BK; Lee S; Kwon OS; Byun SS; Lee SE
    BJU Int; 2012 Dec; 110(11 Pt B):E494-9. PubMed ID: 22540236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy.
    Koie T; Mitsuzuka K; Yoneyama T; Narita S; Kawamura S; Kaiho Y; Tsuchiya N; Tochigi T; Habuchi T; Arai Y; Ohyama C; Yoneyama T; Tobisawa Y
    Int J Clin Oncol; 2015 Feb; 20(1):176-81. PubMed ID: 24771079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
    de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
    J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
    Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
    BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy.
    Ravery V; Boccon-Gibod LA; Dauge-Geffroy MC; Billebaud T; Delmas V; Meulemans A; Toublanc M; Boccon-Gibod L
    Urology; 1994 Sep; 44(3):371-6. PubMed ID: 7521093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.
    Thomas C; Pfirrmann K; Pieles F; Bogumil A; Gillitzer R; Wiesner C; Thüroff JW; Melchior SW
    BJU Int; 2012 Jan; 109(2):214-9. PubMed ID: 21592293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.